Introduction
============

Temporal lobe epilepsy (TLE) with mesial temporal sclerosis (MTS) as defined by magnetic resonance imaging (MRI) is considered to be the most common epilepsy syndrome.^[@B1]^ Its etiology is still unknown.^[@B2],[@B3]^ There is evidence that an activated immune response induced by microglial activation within the hippocampus occurs in patients with TLE.^[@B4]^

On the other hand, autoimmunity might play a role in epilepsy mainly in limbic encephalitis (LE) or multifocal paraneoplastic disorders.^[@B5]^ LE can lead to adult-onset TLE with hippocampal sclerosis (HS).^[@B6]^

Autoimmune encephalitis (AE) with antibodies to neuronal cell surface/synaptic antigens is a recently explained group of neuropsychiatric diseases in which the antibodies react with extracellular epitopes of antigen.^[@B7]^ In contrast to paraneoplastic encephalomyelitis (PEM), in the AE, the associated antibodies appear to mediate the neuronal dysfunction by direct interaction with target antigens, so these effects are reversible and patients with these syndromes often have full recovery after treatment.^[@B8]^

In recent years, several reports have been presented on antigenic targets such as voltage-gated potassium channel (VGKC) complex,^[@B9]-[@B11]^ N-methyl-D-aspartate receptor (NMDA-R), glutamic acid decarboxylase (GAD),^[@B9]-[@B12]^ and glycine receptors, (GlyRs)^[@B9]^ in LE or encephalopathy with seizures as the major symptom.

Due to the hippocampus and limbic structures being enriched with potassium channels, change of the neuronal electrochemical function by this class of antibodies could predispose humans to seizure action.^[@B13]^

A prevalence of 11% has been shown of neurologic autoantibodies, one or more of VGKC, NMDA-R, GAD, or GlyR, in cohorts of patients with new and chronic epilepsy.^[@B9]^ Furthermore, an association between the autoimmune etiology and anti-epileptic drug resistance has been reported and a potential advantage of immunotherapy in improving seizure control has been proposed. This could lead to offering immunotherapy to ameliorate seizure control in some patients with antibodies to VGKC or GAD.^[@B5],[@B11]^ The presence of neuronal antibodies has been reported in patients with MTS.^[@B5]^

Due to the immune aspect of seizures being potentially treatable, it is important to consider any imaging characteristics that can help in the differential diagnosis.

Our aim was to investigate the different prevalence of these autoantibodies in consecutive patients diagnosed with established TLE of unknown cause in two groups: with or without MTS.

Materials
=========

***Participants:*** We included thirty-three adult patients aged 15-50 years, diagnosed with International League Against Epilepsy (ILAE)^[@B2],[@B14],[@B15]^ between 2014 and 2015, who had been followed up by our epilepsy center in Al-Zahra University Hospital, Isfahan, Iran for more than one year. We selected patients with TLE seizures (such as simple partial, complex partial, partial seizure evolving to secondary generalized) from the epilepsy center.

All participants were consented before blood sampling. The Ethics Committee approved the protocol for this study according to Declaration of Helsinki.

The patients with an obvious remote origin such as brain tumor, trauma, central nervous system (CNS) infection, vascular malformation, and generalized epilepsy were excluded.

Clinical findings such as current age, sex, age of onset, all neurological findings, past history of febrile convulsion, past history of encephalitis, family and medical history, medication at the time of serum sampling, electroencephalography (EEG), MRI, and other laboratory findings were collected from the files of patients. All MRI studies were performed with 1.5 T scanners in sagittal and axial planes including T1, T2, fluid-attenuated inversion recovery (FLAIR), and particularly thin section coronal FLAIR and T2 to visualize mesial temporal region optimally.

Thereafter, we divided patients into two groups with and without MTS according to standard visual diagnostic criteria analysis including reduced hippocampal volume, increased T2 signal, and abnormal morphology.^[@B16],[@B17]^ The EEGs were reported by specialists.

***Autoantibody testing:*** The serum samples from all patients were kept at -80 °C. Rat cerebellum and rat hippocampus were used as a standard substrate. Specific transfected cells were used as standard substrates for the monospecific detection of neuronal antibodies by indirect immunofluorescence (IF). To identify in vivo antibodies that bound to tissue antigens, panel antigens were used and the presence of autoantibodies was detected by a fluorophore-conjugated secondary antibody to human immunoglobulin G (IgG) (with EUROIMMUN kit number LOT F1 50803 AA).

Surface antigens such as NMDA-R, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R), leucine-rich glioma-inactivated protein 1 (LGI1), gamma-aminobutyric acid (GABA) B receptor (GABAB-R), contactin-associated protein-like 2 (CNTNAP2), GAD, and GlyR as well as neuronal nuclear antigens such as CV2, Tr \[Delta and Notch-like epidermal growth factor-related receptor (DNER)\], amphiphysin, paraneoplastic antigen Ma2 (PNMA2), Ri, Yo, Hu, recoverin ,titin, and Zic4 (with kit number LOT D1 50204 AB) were evaluated with IF.

Antinuclear antibodies (ANAs), double-stranded deoxyribonucleic acid (dsDNA), and antibody against substances in the blood such as anti-phospholipid (APL) were detected by enzyme-linked immunosorbent assay (ELISA) technique.

Antigens were incubated with diluted patient serum samples. Specific antibodies attached to the antigens on the specific substrate slide sections incubated for 30 minutes at room temperature of +18 to +25 °C. In the second step, the attached antibodies were stained with fluorescein-labelled anti-human secondary antibodies and made visible with a fluorescence microscope. The non-transfected cells were used as a control to enable differentiating potential unspecific reactivity. The intensity of specific fluorescence was called fluorescence intensity level. The intensity levels were quantified and arranged visually based on dilution steps. The dilution starting point for this measurement system was 1:10 in phosphate buffered saline (PBS)-Tween (PBS-T); if no reaction was observed in 1:10, it was considered as negative, and if reaction was indicated, it was measured as weakly positive. Samples can be more diluted by a factor of 10 so that the dilution series is 1:100 and 1:1000 which were considered as moderate and severe positively reaction, respectively.

Results
=======

A total of 33 consecutive patients with epilepsy, 17 (51.5%) with MTS (12 unilateral, 5 bilateral) \[mean and standard deviation (SD) of age: 31.47 ± 13.44 years\] and 16 (48.5%) without MTS (mean and SD of age: 34.69 ± 13.44 years), were included in this study. The clinical and laboratory features and some comorbidity of the patient groups with and without autoantibodies are shown in [table 1](#T1){ref-type="table"}. No significant difference was observed between seropositive and seronegative patients in type of seizures and MRI findings (MTS *vs.* non-MTS).

The investigated autoantibodies were present in 16 patients (10 women, 6 men; mean age: 35.06 ± 12.47 years). All of the serum samples were weakly positive (dilution 1:10) and did not react when more diluted (1:100 or 1:1000). Antibodies were detected against GAD in 1 (3%), APL in 1 (3%), NMDA-R in 2 (6.1%), CV2 in 1 (3.0%), Tr in 1 (3.0%), GABA in 11 (33.3%), recoverin in 1 (3.0%), dsDNA in 1 (3.0%) of our patients with focal epilepsy ([Table 2](#T2){ref-type="table"}). In MTS group, we found GABA antibodies in 4 (23.5%) patients, NMDA-R antibodies in 1 (5.9%), recoverin antibody in 1 (5.9%), GAD, Tr, and CV2 antibodies in 1 (5.9%), and finally dsDNA in 1 (5.9%), patient. Whereas in non-MTS group, 7 patients were positive for antibodies to GABA and 1 had both NMDA and APL antibodies.

###### 

Comparison of the clinical features of patients with and without autoantibodies

  --------------------------------------------------------------------------------------------------------------------------
  **Variable**                      **Seropositive patients (n = 16)**   **Seronegative patients (n = 17)**   **P**   
  --------------------------------- ------------------------------------ ------------------------------------ ------- ------
  Sex                               Women                                10                                   8       0.37

  Men                               6                                    9                                            

  Age at serum sampling (year)      35.5                                 28                                   0.40    

  Median: \[Q1-Q3\]                 \[28.5-46.0\]                        \[21-39\]                                    

  Age at onset of epilepsy (year)   28                                   18                                   0.33    

  Median: \[Q1-Q3\]                 \[18.5-34.5\]                        \[9-32\]                                     

  Seizure type (GTC/CPS) (8/25)\    4/12                                 4/13                                 0.90    
  Women: 18 (5/13)\                                                                                                   
  Men: 15 (3/12)                                                                                                      

  History of encephalitis           1                                    0                                            

  MRI findings                                                                                                0.60    

  MTS/non-MTS: (16/17)              8/8                                  8/9                                          
  --------------------------------------------------------------------------------------------------------------------------

GTC: Generalized tonic-clonic; CPS: Complex partial seizure; MTS: Mesial temporal sclerosis; MRI: Magnetic resonance imaging

###### 

The clinical and laboratory features of the antibody-positive patients

  -------------------------------------------------------------------------------------------------------------------------------------------------
  **Antibody**   **Age**\     **Sex**   **Age of**\          **Epilepsy**\   **Positive**\   **MRI**\       **History of**\    **Treatment**
                 **(year)**             **seizure onset**\   **syndrome**    **family**\     **findings**   **encephalitis**   
                                        **(year)**                           **history**                                       
  -------------- ------------ --------- -------------------- --------------- --------------- -------------- ------------------ --------------------
  NMDA/APL       14           Male      7                    SG              \-              Cortical\      \-                 Sodium valproate,\
                                                                                             sclerosis                         topiramate

  NMDA           36           Female    29                   SG              \+              Bilateral\     \-                 Sodium valproate,\
                                                                                             MTS                               carbamazepine

  Recoverin      35           Female    23                   CPS             \-              Unilateral\    \-                 Sodium valproate,\
                                                                                             MTS                               carbamazepine

  GAD/Tr/CV2     30           Female    15                   CPS             \-              Unilateral\    \-                 Depakin
                                                                                             MTS                               

  GABA           25           Female    7                    CPS             \-              Normal         \-                 Sodium valproate,\
                                                                                                                               Oxcarbazepine,\
                                                                                                                               lamotrigine

  GABA           48           Female    41                   SG              \-              Normal         \-                 Sodium valproate,\
                                                                                                                               carbamazepine

  GABA           20           Male      14                   CPS             \-              Normal         \-                 Sodium valproate,\
                                                                                                                               topiramate

  GABA           28           Male      7                    CPS             \-              Bilateral\     \+                 Depakin
                                                                                             MTS                               

  GABA           35           Male      7                    SG              \-              Normal         \-                 Sodium valproate,\
                                                                                                                               Oxcarbazepine

  GABA           55           Male      20                   CPS             \-              Normal         \-                 Sodium valproate,\
                                                                                                                               carbamazepine,\
                                                                                                                               lamotrigine

  GABA           36           Female    7                    CPS             \-              Normal         \-                 Sodium valproate,\
                                                                                                                               carbamazepine

  GABA           53           Male      12                   CPS             \-              Unilateral\    \-                 Sodium valproate,\
                                                                                             MTS                               carbamazepine

  GABA           48           Female    12                   CPS             \-              Unilateral\    \-                 Sodium valproate,\
                                                                                             MTS                               carbamazepine

  GABA           32           Female    7                    CPS             \-              Normal         \-                 Sodium valproate,\
                                                                                                                               carbamazepine

  GABA           38           Female    20                   CPS             \-              Unilateral\    \-                 Sodium valproate,\
                                                                                             MTS                               carbamazepine,\
                                                                                                                               clonazepam

  dsDNA          40           Female    33                   SG              \-              Unilateral\    \-                 Sodium valproate,\
                                                                                             MTS                               carbamazepine,\
                                                                                                                               lamotrigine
  -------------------------------------------------------------------------------------------------------------------------------------------------

NMDA: N-methyl-D-aspartate; APL: Anti-phospholipid; GAD: Glutamic acid decarboxylase; GABA: Gamma-aminobutyric acid; dsDNA: Double-stranded deoxyribonucleic acid; SG: Secondary generalization; CPS: Complex partial seizure; MTS: Mesial temporal sclerosis; MRI: Magnetic resonance imaging

Discussion
==========

Neuronal antibodies have been found in patients with epilepsy in whom seizures were the main presenting symptom.^[@B9],[@B18],[@B19]^ These antibodies may be causative or simply a marker of underlying inflammatory process. A new idea has now been suggested as "autoimmune epilepsy".^[@B5],[@B20]^ Autoimmune antibodies may be the cause of a small proportion of epilepsies but the importance of identifying these cases is because many of the affected patients can benefit from immunotherapy.^[@B21]^

We discovered that a number of patients with focal epilepsy with either unknown cause or MTS showed various neuronal antibodies, GABA antibodies being the most common in 11 (33.3%), followed by NMDA-R in 2 (6.1%), GAD in 1 (3.0%), APL in 1 (3.0%), CV2 in 1 (3.0%), Tr in 1 (3.0%), recoverin in 1 (3.0%), and dsDNA in 1 (3.0%) of the patients. We found autoantibodies in half of the patients with TLE, which is a higher prevalence rate than all previous reports. For example, Ekizoglu, et al.^[@B18]^ presented a lower prevalence rate for autoantibodies in one sixth of their 81 patients with focal epilepsy. Our study includes general antibodies and has a small sample size, whereas in the mentioned study, specific neuronal antibodies, for example VGKC complex, were studied. In the study done by [Gozubatik-Celik,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gozubatik-Celik%20G%5BAuthor%5D&cauthor=true&cauthor_uid=28675819)et al., autoantibodies were significantly responsive to immunotherapy in focal epilepsy when compared to the control group (13.8%).^[@B22]^

Consequently, 33.3% of our TLE cases were shown to be concomitant with antibodies to the GABA-Rs. Autoantibodies were directed against the enzyme GAD, responsible for synthesis of the inhibitory neurotransmitter GABA, which has been reported in a number of patients with various forms of epilepsy.^[@B20]^

In patients with epilepsy, the frequency of GAD antibody ranges from 0%^[@B18]^ to 7%.^[@B10]-[@B12],[@B19]^ In a prospective study of 253 patients with epilepsy, 15 (6%) had GAD antibodies compared to 3% in ours. Previous studies have shown that 90% of patients with higher levels of GAD antibodies had TLE,^[@B12],[@B19]^ describing potentially pathogenic antibodies in focal epilepsy. It is notable that some of the AMPA and GABAB-R antibody-positive patients had GAD antibodies.^[@B23],[@B24]^ In addition to the presence of GAD antibody in patients with GABA-R antibodies, these patients often have other autoantibodies \[e.g., thyroid peroxidase (TPO), ANA, GAD65\], reflecting a tendency to autoimmunity.^[@B25]^

GABA-Rs are extensively expressed in the brain especially in the hippocampus, thalamus, and cerebellum.^[@B26]^ Therefore, it is reasonable that in our study, patients with focal epilepsy with or without MTS were accompanied with positive antibodies against GABA-Rs, suggesting a potential role of GABA autoimmunity in the pathogenesis of our patients' symptoms. Most seizures with GABA antibody appear to have a temporal-lobe onset with secondary generalization (SG), while some patients have status epilepticus (SE) or subclinical seizures demonstrated in EEG.^[@B27]^

In contrast to other AE in which the brain MRI either is normal or shows predominant involvement of the limbic system, all patients with high titer serum or cerebrospinal fluid (CSF) GABA antibodies had extensive MRI abnormalities on FLAIR and T2 imaging with multifocal cortical-subcortical involvement.^[@B25]^ In our study, in 11 patients with GABA-R antibodies, 7 patients had normal MRI, 3 patients had unilateral MTS, and only 1 patient had bilateral MTS. However, in another study, evaluation of children with focal epilepsy showed that any distinctive features distinguishing antibody-positive patients from those without antibodies.^[@B28]^

One cohort study discovered that NMDA-R, GlyR, and VGKC-complex antibodies were most prevalently found in patients with or without AE.^[@B29]^ Another study has shown a GlyR antibody-positive case with an immunotherapy-responsive isolated mesial temporal lobe SE.^[@B30]^ It is supposed that this condition is greatly underdiagnosed and undertreated.^[@B31],[@B32]^ The immunological trigger of AE is varied. It varies from the presence of a systemic tumor that expresses the target neuronal proteins or a viral-like illness. The latter has been supported by recent studies showing the development of AE after herpes simplex encephalitis (HSE).^[@B33]^ In our study, one patient with GABA-R antibody had encephalitis.

Also there is evidence suggesting that autoimmune LE associated with neuronal antibody might induce temporomedial inflammation and result in development of adult-onset TLE with MTS.^[@B6]^ LE cannot be distinguished from the MRI but MTS can.^[@B6]^ If these imaging findings are recognized in the beginning of the process of the disease, there is a possibility that unnecessary invasive procedures can be prevented and immunotherapy can be administered early on.

There are limitations to our study. We understand that our group was small and no statistical adjustments for multiple comparisons were done. Therefore, further studies with large samples are needed to draw firm conclusions and to evaluate immunotherapy efficacy in focal seizures particularly in intractable epilepsy or SE.

Conclusion
==========

Our study confirms the findings of other studies showing anti-neuronal antibody presence in some patients with focal epilepsy. Autoimmunity may not be a causative factor like in many chronic neurological disorders; however, anti-neuronal autoimmunity may be a factor in seizure causation, and immunomodulation may be of benefit in a subgroup of these patients.

This work was funded by the Neurosciences Research Center (grant number: 294021). We are grateful to all of the patients who helped us in our project.

Notes:
======

**How to cite this article:** Ansari B, Etemadifar M, Najafi M, Nasri M, Meamar R. Neuronal autoantibodies in focal epilepsy with or without mesial temporal sclerosis. Iran J Neurol 2019; 18(1): 13-8.

Conflict of Interests
=====================

The authors declare no conflict of interest in this study.
